Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study to evaluate the safety and immunogenicity of HXP-GPOVac compared with AZD1222
TCTR20220120002Phase 3Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant NDV vectored vaccine for SARS-CoV-2 in coronavirus disease 2019 (COVID-19), sponsored by Government Pharmaceutical Organization. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
recombinant NDV vectored vaccine for SARS-CoV-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220120002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220120002.